Lucid Diagnostics’ Post

Episode 5, "Regionalized Point-of-Care approach using an Automated Closed System instrument with sterile disposable set" completes our latest INNOVATION VAULT™ Series, NexGen CAR T-cell Therapy; Democratization via Advanced Point-of-Care Production and Applications. This democratization approach to CAR T-cell therapy will significantly impact patient care. By cutting costs, shortening manufacturing timelines, reducing contamination risks, and improving treatment outcomes, the automated closed-system instrument with disposable set presents a revolutionary solution that aims to cater to a larger patient population. Tune into episode 5 and catch up on previous episodes diving into the fascinating world of cancer treatment advancements and MIDI's pivotal role in shaping the future of CAR T-cell therapy. Learn how this breakthrough approach is set to transform the landscape of cancer care, bringing hope and healing to millions of lives. #podcast #CARTcellTherapy #cancertherapy #cancertreatment #innovation #InnovationVault

🩻 Health technology is one of the fastest-growing high-tech export segments in Finland – and recent news showcase that the industry is getting a boost! 💡 Did you know that the companies making up the industry tend to conduct both their #research and #development, and #manufacturing operations in Finland. They produce not only medical devices, such as imaging and measuring tools, but also digital services that support their product offering. Read more ➡️ https://lnkd.in/dp9zcWTC Good News from Finland

Driving #precision medicine using digital biomarkers! The recent Nature Portfolio paper https://lnkd.in/d-mx-2xT discusses important parameters about how the power of digital biomarkers can drive precision medicine. "While [digital] biomarkers provide clear opportunity and increased dimensionality of data sources, the increased array of sensors and, thus, data capture needs to be carefully considered ..." At Koios Care we share some insights about how we transform multimodal raw data passively captured in-the-wild into clinically meaningful indicators for #Parkinson's Disease and beyond.  We share some key insights on our whitepaper attached. We will be in the Novartis Pavilion on #April 9th for #GenAI4Pharma in #Basel to showcase some of the latest advancements in #GenAI-based technology and improve clinical development.

We are very pleased to welcome Gradient Denervation Technologies (“Gradient”)  to the Thuja family.  Gradient, the seventh investment from our third fund, is the latest addition to the Thuja portfolio of companies. Gradient is a clinical-stage company developing an innovative, minimally invasive ultrasound-based catheter device for the treatment of pulmonary hypertension. Gradient will initially focus on patients with pulmonary hypertension due to left-sided heart disease, which affects several million individuals across the US and Europe. There are currently no targeted treatments available for this disease, which has significant negative impacts on quality and length of life. Evan Castiglia, Partner at Thuja says,: “Gradient has significant potential to improve the care of patients with pulmonary hypertension due to left heart disease, a patient group with a substantial need for better treatment solutions. We are excited to support the Gradient team as they pursue this mission.”   We congratulate CEO Martin Grasse and his team with the €14M Series A funding round and look forward to working with co-investors Asabys Partners and Sofinnova Partners. #thujafamily #venturecapital #earlystageinvestment #medicaldevice #technology #shapingthefuture #medtech

Trax Molecular Diagnostics pioneers precision with swift and accurate diagnoses, amplifying donor compatibility. 🧬 Unveiling a new era of personalized treatment plans, every patient's journey is uniquely sculpted for optimal outcomes. 🚀 Our breakthroughs redefine possibilities, ensuring earlier detection, seamless donor matches, and elevated success rates. 🌈 Join us in the evolution of transplant medicine, where innovation meets compassion, transforming lives one diagnosis at a time. 🩺✨ #trax #traxdiagnostics  

Trax Molecular Diagnostics pioneers precision with swift and accurate diagnoses, amplifying donor compatibility. 🧬 Unveiling a new era of personalized treatment plans, every patient's journey is uniquely sculpted for optimal outcomes. 🚀 Our breakthroughs redefine possibilities, ensuring earlier detection, seamless donor matches, and elevated success rates. 🌈 Join us in the evolution of transplant medicine, where innovation meets compassion, transforming lives one diagnosis at a time. 🩺✨ #trax #traxdiagnostics  

Excited for #PEGSBoston? Catch Arnout Van Hyfte presenting "LENSᵃⁱ: Empowering Diversity-Driven Discovery, Intelligent Lead Selection and Optimization" on May 16th at 4:05 pm. Also, make sure to visit us at booth 307 to chat about the exciting role AI is playing in #biotech innovation. See you there! #PEGS2024 #Antibodies #DrugDiscovery #LENSai IPA (ImmunoPrecise Antibodies)

The #digitalpathology ecosystem is complex and crowded! "It's so hard to tell at face value what part of the ecosystem each company is working on", says James Sweeney, President of PathAI Diagnostics. Read our latest blog that breaks down the digital pathology market and describes the various verticals vendors may fall into across the ecosystem. Read more: https://lnkd.in/gP4bjf-Q

To me, precision medicine, or “personalized medicine”, is the future in healthcare. It is encouraging that new interventions will be customized to patients’ specific needs in disease prevention and treatment, considering their differences in genetics and external factors.    That’s why I am absolutely thrilled to host our @JLABS symposium on precision medicine in November. #lifesciences #startups and innovators are invited to join: https://lnkd.in/efW6zdwN   Let’s discuss the challenges in developing diagnostics, biomarkers, tools for patient stratification and digital applications for real-world evidence studies. Startups, established companies, key opinion leaders as well as J&J experts in precision medicine will share insights and best practices. #jnjinnovation #mycompany

For Elena Fernandez Kleinlein To me, precision medicine, or “personalized medicine”, is the future in healthcare. It is encouraging that new interventions will be customized to patients’ specific needs in disease prevention and treatment, considering their differences in genetics and external factors. For me too! For you? #startups #lifesciences #precisionmedicine